Evaluation of ATOX1 as a Potential Predictive Biomarker for Tetrathiomolybdate Treatment of Breast Cancer Patients with High Risk of Recurrence

• Published in: Biomedicines Vol. 9; no. 12; p. 1887
• Main Authors: Blockhuys, Stéphanie, Hildesjö, Camilla, Olsson, Hans, Vahdat, Linda, Wittung-Stafshede, Pernilla
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 12.12.2021; MDPI
• Subjects: Antibodies; ATOX1; Biomarker; Biomarkers; Breast cancer; Cancer therapies; Cell adhesion & migration; Cell migration; Clinical trial; Clinical trials; Communication; Copper; Copper depletion; Cytoplasm; Enzymes; Event-free survival; Metastases; Metastasis; Patients; Proteins; Tetrathiomolybdate; Tumors; clinical trial; event-free survival; breast cancer; copper depletion; biomarker; ATOX1; tetrathiomolybdate
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines9121887

Copper plays a key role in cancer metastasis, which is the most common cause of cancer death. Copper depletion treatment with tetrathiomolybdate (TM) improved disease-free survival in breast cancer patients with high risk of recurrence in a phase II clinical trial. Because the copper metallochaperone ATOX1 was recently reported to drive breast cancer cell migration and breast cancer migration is a critical factor in metastasis, we tested if ATOX1 expression levels in primary tumor tissue could predict the TM treatment outcome of breast cancer patients at high risk of recurrence. We performed ATOX1 immunohistochemical staining of breast tumor material (before TM treatment) of 47 patients enrolled in the phase II TM clinical trial and evaluated ATOX1 expression levels in relation with patient outcome after TM treatment. Our results show that higher ATOX1 levels in the tumor cell cytoplasm correlate with a trend towards better event-free survival after TM treatment for triple-negative breast cancer patients and patients at stage III of disease. In conclusion, ATOX1 may be a potential predictive biomarker for TM treatment of breast cancer patients at high risk of recurrence and should be tested in a larger cohort of patients.